C5-Targeting dsRNA Composition for Consistent Hemolysis Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for complement component C5-associated diseases, such as paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome, require frequent high-dose infusions and have variable efficacy, leading to breakthrough hemolysis and significant costs, necessitating the development of alternative and combination therapies that provide consistent efficacy and minimize hemolysis.
Innovation Solution
The use of double-stranded ribonucleic acid (dsRNA) agents that target and inhibit the expression of the C5 gene through RNA-induced silencing complex (RISC)-mediated cleavage, utilizing specific dsRNA sequences to reduce C5 gene expression, potentially offering a more consistent and effective treatment approach.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anti-C5 antibody therapy (eculizumab) is used, then complement component C5 expression is inhibited, but frequent high-dose infusions are required and breakthrough hemolysis occurs
Solution Approach 1:
The patent replaces the mechanical/procedural approach of frequent infusions with a molecular mechanism (dsRNA-mediated RISC cleavage) that provides sustained inhibition. The dsRNA agents are administered less frequently and achieve consistent C5 inhibition through RNA interference, eliminating the need for continuous monitoring and frequent dose adjustments required by antibody therapy.
Solution Approach 2:
The patent changes the pharmacokinetic parameters by using dsRNA agents with different half-lives and clearance characteristics compared to antibodies. This allows for extended dosing intervals while maintaining consistent C5 inhibition levels, thereby reducing infusion frequency and improving treatment reliability.
2Reliability
If anti-C5 antibody therapy is used, then C5 expression is inhibited, but variable efficacy leads to breakthrough hemolysis
Solution Approach 1:
The patent substitutes antibody-mediated inhibition with direct RNA cleavage mechanism. The dsRNA agents bind to C5 mRNA and facilitate RISC-mediated cleavage, providing a more reliable and consistent inhibition mechanism that eliminates breakthrough hemolysis by ensuring continuous C5 protein synthesis blockage.
Solution Approach 2:
The patent employs feedback mechanisms through the RISC complex that continuously monitors and cleaves C5 mRNA as it is transcribed. This feedback loop ensures consistent C5 inhibition by dynamically responding to any C5 protein production, thereby preventing breakthrough hemolysis.
3Reliability
If anti-C5 antibody therapy is used, then C5 expression is inhibited, but significant costs are incurred
Solution Approach 1:
The patent uses small molecular weight dsRNA agents that can be synthesized at lower cost compared to large monoclonal antibodies. These dsRNA agents are administered less frequently, reducing the total quantity of therapeutic substance required and thereby significantly lowering treatment costs while maintaining efficacy.
Solution Approach 2:
The patent changes the molecular size and synthesis parameters of the therapeutic agent from large proteins (antibodies) to small nucleic acid molecules (dsRNA). This parameter change enables cost-effective production and reduces the economic burden of treatment while maintaining therapeutic effectiveness.
4Ease of manufacture
If dsRNA agents are used, then C5 gene expression is inhibited through RISC-mediated cleavage, but the mechanism is novel and requires validation
Solution Approach 1:
The patent uses synthetic dsRNA sequences that are exact copies of the target C5 mRNA regions. These synthetic copies are designed to perfectly complement the C5 mRNA and facilitate RISC-mediated cleavage. The copying approach simplifies manufacturing by using standardized nucleotide synthesis methods while ensuring reliable target engagement.
Solution Approach 2:
The patent performs preliminary characterization and validation of the dsRNA sequences against the C5 gene target before clinical application. This preliminary action includes in vitro and in vivo studies to confirm RISC-mediated cleavage and C5 inhibition, thereby validating the mechanism before widespread use.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The dsRNA agents effectively inhibit C5 gene expression, providing a potentially more reliable and less invasive treatment for complement component C5-associated diseases, reducing the need for frequent infusions and minimizing breakthrough hemolysis.
Implementation Method 1
The use of double-stranded ribonucleic acid (dsRNA) agents that target and inhibit the expression of the C5 gene through RNA-induced silencing complex (RISC)-mediated cleavage
Data Source
AI summary
The invention relates to iRNA, e.g., double stranded ribonucleic acid (dsRNA), compositions targeting the complement component C5 gene, and methods of using such iRNA, e.g., dsRNA, compositions to inhibit expression of C5 and to treat subjects having a complement component C5-associated disease, e.g., paroxysmal nocturnal hemoglobinuria.